| IPO Company Profile © ipodata.com |
| Message Board | Quote | Chart | News | SEC Filings | Peer IPO Companies |
| Dr. Reddy's Laboratories Limited |
| 7-1-27 Ameerpet, Hyderabad, India 500 016 |
| Business Description | The company is a leading Indian pharmaceutical company that develops, manufacturers and markets a wide range of pharmaceutical products in India and internationally. |
| Offering Information Company has | |||
| Trading As | RDY (NYSE) | Industry | Pharmaceutical (SIC 2834) |
| Type of Stock Offered | American Depositary Receipts | Filing Date | 3/26/2001 |
| Domestic Shares Offered | 11,500,000 | Offer Date | 4/11/2001 |
| Foreign Shares Offered | 0 | Filing Range | $12.94 - $13.00 |
| Company Shares | 11,500,000 | Offer Price | $10.04 |
| Selling Shrhldrs Shares | 0 | Gross Spread | $0.550 |
| Gross Proceeds | $115,460,000 | Selling | $0.331 |
| Expenses | - - | Reallowance | $0.100 |
| Post-IPO Shares | 74,677,560 | Employees | - - |
| Primary Underwriting Group | ||
| Underwriter Name | Participation | Underwriter Phone |
| Merrill Lynch & Co. | Lead Manager | (212) 449-4600 |
| ABN Amro Roth | Co-manager | (212) 314-1080 |
| Credit Lyonnais Securities (USA) Inc. | Co-manager | (212) 428-6176 |
| Income Statement and Cash Flow Summary | |||||||
| Prior Audited Income |
Latest Unaudited Income | ||||||
| Full Year Audited Figures | 6 Months Ending | ||||||
| Figures in U.S. millions except per share data | 3/31/2000 | 9/30/2000 | |||||
| Revenues | - | - | - | - | 120.801 | - | 80.738 |
| Income from Oper. | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | 7.250 | - | 4.900 |
| E.P.S | - | - | - | - | 0.540 | - | 0.360 |
| Revenue Growth (%) | - | - | - | - | - | ||
| Net Income Growth (%) | - | - | - | - | - | ||
| Oper. Profit Margin (%) | - | - | - | - | - | - | - |
| Net Profit Margin (%) | - | - | - | - | 6.00 | 6.07 | - |
| Cash Flow - Oper. | 14.52 | - | 12.93 | ||||
| Cash Flow - Inv. | -28.66 | - | -5.09 | ||||
| Cash Flow - Fin. | 14.53 | - | -7.90 | ||||
| Balance Sheet Summary and Financial Ratios | |||||
| Balance sheet as of: 9/30/2000 | Financial Ratios | ||||
| Total Assets | 154.67 | Current Assets | - | Current Ratio | - |
| Total Liab. | 85.91 | Current Liab. | - | Debt Ratio | 55.54% |
| Total Equity | 68.76 | Working Cap. | - | Debt to Equity Ratio | 1.25 |
| Cash | 9.96 | Return on Assets | 3.17% | ||
| Use Of Proceeds |
The proceeds from the proposed offering will be used for drug discovery and development, for acquisitions and the establishment of marketing operations, for working capital and general corporate purposes. |
| Legal Counsel Registrar Auditor | |
| Issuer's Law Firm | Clifford Chance Rogers & Wells LLP |
| Bank's Law Firm | Milbank, Tweed, Hadley & McCloy |
| Auditor | KPMG Accountants N.V. |
| Send us feedback if you would like to request that we hyperlink a firm on this page | |